戻る Agenda
Session 5: Post-authorisation evidence generation for ATMPs
Session Chair(s)
Keith Wonnacott, PHD
Vice President, Regulatory Affairs
Lexeo Therapeutics, United States
ATMPs have several unique considerations such as: they are often developed for rare diseases, they have unique long-term safety concerns, and they often show compelling efficacy early in development. Therefore, there is a significant need to gather data and/or follow patients outside of the clinical trial setting. Increasingly, we are hearing discussions of how registries and real-world evidence can be used to address some of the regulatory and payer expectations post-authorisation. This session will discuss expectations and experience in generating and utilising these innovative approaches.
Topics explored in this Session:
- Registries Supporting RWE | Big Data.
- Resolving HTA/Payer Uncertainties with RWE
- RWE for decision making for PLEG and for approval.
Speaker(s)
Post-authorisation evidence generation for ATMPs
Nuria Semis-Costa, MSC
European Medicines Agency, Netherlands
Scientific Specialist (Risk Management)
Registries enabling RWE generation and regulatory/payer discussions
Ian Winburn
Pfizer Biopharmaceuticals Group, United States
Vice President, Global Medical Lead Haemophilia, Endocrine and IEM
Experience with post-authorisation data generation, registries, and the use of RWE
Yanni Hao, PHD
Novartis, United States
Executive Director Cell & Gene, Global RWE & Data Science